CytRx Corporation, a bio pharmaceutical specializing firm in oncology, announced its results for first quarter of FY-2015.
Quarterly EPS downs by$0.10 to -$0.31, whereas Revenues rise by 55.2% to $15.69 Million.
View the full earnings release here.
CytRx Corporation, a bio pharmaceutical specializing firm in oncology, announced its results for first quarter of FY-2015.
Quarterly EPS downs by$0.10 to -$0.31, whereas Revenues rise by 55.2% to $15.69 Million.
View the full earnings release here.